Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York

23092015 PR ladenburg conf_EN

Published 23 September 2015
Categorized as 2015, Press release

Transgene Reports Financial Results for First Six Months of 2015 (interim report)

20150910 – PR 2015 H1 results final

Published 10 September 2015
Categorized as 2015, Press release

Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

20150908 PR TG4010 IASLC revised – BIS

Published 8 September 2015
Categorized as 2015, Press release, TG4010

Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer

19 August 2015_PR_IASLC curtain raiser_ENG

Published 19 August 2015
Categorized as 2015, Press release, TG4010

Transgene plans restructuring to focus on research and development

20150629 PR 29 juin fin

Published 29 June 2015
Categorized as 2015, Press release

Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)

20150601 PR TG4010 TIME results_ASCO 2015_FINAL

Published 1 June 2015
Categorized as 2015, Press release, TG4010

Transgene Announces Participation at Upcoming Investor Events

20150518 May thru July 2015 IR events_ver 1 ENG

Published 18 May 2015
Categorized as 2015, Press release

Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015

20150423 – US – EASL2015 TG1050

Published 23 April 2015
Categorized as 2015, Press release, TG1050

Transgene Reports First Quarter 2015 Financial Results

20150422 PR US Q1 2015

Published 22 April 2015
Categorized as 2015, Press release

Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody

20150421 AACR 2015_English

Published 21 April 2015
Categorized as 2015, Press release, TG3003, TG4010

Posts pagination

Newer posts Page 1 … Page 32 Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu